Evaluating 150 non-metastatic pancreatic ductal adenocarcinoma patients undergoing neoadjuvant FOLFIRINOX chemotherapy, researchers compared biochemical (CA 19-9 normalization) and radiologic responses. Three groups were identified: biochemical responders (BR+), radiology-only responders (BR-/RR+), and non-responders (BR-/RR-). BR+ showed the highest 3-year overall survival (71.0%), significantly better than BR-/RR+ (53.6%) and BR-/RR- (33.1%). Regardless of neoadjuvant response, completing adjuvant chemotherapy improved survival. This study advocates the feasibility of biochemical response assessment for prognosis prediction and highlights the potential benefit of adjuvant chemotherapy post neoadjuvant treatment.
Journal Article by Yun WG, Han Y (…) Jang JY et 4 al. in Ann Surg Oncol
© 2023. Society of Surgical Oncology.